chemXplore tracks 11 projects in Slovakia, of which one is active.
Of the active ones, 1 expansion.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
€1bn Europe-wide auction for industrial process-heat decarbonisation; bidding opens early Dec 2026. Supports electrification, renewable heat and SMRs with a fixed premium per tCO2.
Aligns businesses by role, assigns roles to six German sites, and shifts investment to Asia/Americas; launches growth projects in Canada and Slovakia, funded by cost cuts.
CHMP limits ipidacrine to specific neuropathies, Alzheimer’s, intestinal atony and certain stroke/TBI recovery uses; removes several neuritis and demyelinating indications; cautions >80 mg/day.
SAF reached 1.1 Mt (2.8% share), a near sixfold rise from 2024; supplied at 121 airports, 84% produced in the EU, and 18 Member States host production projects.
EUR 80m upgrade adds downstream fermentation capacity for complex pharma intermediates, targets completion early 2028 and about 50 new jobs; site runs on 100% green electricity.
High natural gas and emission allowance costs could force cuts to ammonia output, pushing fertilizer prices beyond farmers’ budgets and threatening European harvests.
Q2 results: revenue PLN 76.5bn, LIFO EBITDA PLN 13.9bn, net profit PLN 7.7bn; record foreign retail profits and H1 capital expenditure PLN 14.7bn.
active / all projects
